German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations-Reference-Cited by-同舟云学术

German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations

Published:2021-07 Issue:7 Volume:19 Page:1092-1115
ISSN:1610-0379
Container-title:JDDG: Journal der Deutschen Dermatologischen Gesellschaft
language:en
Short-container-title:JDDG: Journal der Deutschen Dermatologischen Gesellschaft

Author:

Nast Alexander¹,Altenburg Andreas²,Augustin Matthias³,Boehncke Wolf‐Henning⁴,Härle Peter⁵,Klaus Joachim⁶,Koza Joachim⁶,Mrowietz Ulrich⁷,Ockenfels Hans‐Michael⁸,Philipp Sandra⁹,Reich Kristian¹⁰,Rosenbach Thomas¹¹,Schlaeger Martin¹²,Schmid‐Ott Gerhard¹³,Sebastian Michael¹⁴,Kiedrowski Ralph¹⁵,Weberschock Tobias¹⁶,Dressler Corinna¹

Affiliation:

1. Department of Dermatology Venereology and Allergology Division of Evidence‐Based Medicine (dEBM) Charité – Universitätsmedizin Berlin corporate member of Freie Universität Berlin Humboldt‐Universität zu Berlin and Berlin Institute of Health Berlin Germany

2. Dermatology Venereology and Allergology Immunology Center Dessau Municipal Hospital Dessau Germany

3. German Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Center Hamburg‐Eppendorf (UKE) Hamburg Germany

4. Department of Dermatology and Venereology University Hospital of Geneva Geneva Switzerland

5. Katholisches Klinikum Mainz Mainz Germany

6. Deutscher Psoriasis Bund e.V. Germany

7. Psoriasis Center Department of Dermatology Venereology Allergology University Hospital Schleswig‐Holstein Campus Kiel Kiel Germany

8. Department of Dermatology and Allergy Klinikum Hanau Hanau Germany

9. Dermatology practice Oranienburg Germany

10. Center for Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg‐Eppendorf Hamburg Germany

11. Dermatology practice Osnabrück Germany

12. Dermatology practice Oldenburg Germany

13. Berolina Klinic Löhne Germany

14. Dermatology practice Mahlow Germany

15. Dermatology practice Selters Germany

16. Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt/Main, Germany and Working group Evidence‐based Medicine Frankfurt Institute for General Practice, Goethe University Frankfurt Frankfurt/Main Germany

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ddg.14507

Reference139 articles.

1. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – pdate 2015 – Short version – EDF in cooperation with EADV and IPC;Nast A;J Eur Acad Dermatol Venereol,2015

2. European S3‐Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC;Nast A;Journal of the European Academy of Dermatology and Venereology: JEADV,2017

3. Role of Methotrexate in the Management of Psoriatic Arthritis;Elmamoun M;Drugs,2018

4. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta‐analysis;McInnes IB;J Comp Eff Res,2018

5. A head‐to‐head comparison of the efficacy and safety of ixekizumab and adalimumab in biological‐naive patients with active psoriatic arthritis: 24‐week results of a randomised, open‐label, blinded‐assessor trial;Mease PJ;Ann Rheum Dis,2020

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Head-to-Head-Studien bei Psoriasis und Psoriasisarthritis;Zeitschrift für Rheumatologie;2024-08-14

2. Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation;Rheumatology and Immunology Research;2024-03-01

3. Paradoxe Hautreaktion auf Certolizumab mit Überlappung neutrophiler Dermatosen;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-03

4. Nicht‐Biologika‐Immunsuppressiva bei entzündlichen und autoimmunen Hautkrankheiten;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-03

5. Paradoxical skin reaction to certolizumab, an overlap of neutrophilic dermatoses;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-02-09